Table 2 Previous and concomitant treatments of the 28 patients with progressive ASS-ILD treated with Rituximab

Need for intravenous methylprednisolone boluses

10 (36%)

Number of prior immunosuppressants used (mean)

2 (range, 1-5)

Prior treatment with Mycophenolate

20 (71%)

Prior treatment with Azathioprine

13 (46%)

Prior treatment with Cyclophosphamide

3 (11%)

Prior treatment with Tacrolimus / Cyclosporine A

13 (46%) / 3 (11%)

Prior treatment with Methotrexate

4 (14%)

Prior treatment with Leflunomide

1 (4%)

Prior treatment with Hydroxychloroquine

3 (11%)

Need for intravenous immunoglobulins

7 (25%)

Rituximab Monotherapy, n (%)

1 (4%)

RTX plus a concomitant immunosupressant, n (%)

27 (96%)

Mycophenolate

13 (46%)

Tacrolimus

10 (36%)

Azathioprine

3 (11%)

Ciclosporine A

1 (4%)

Mean dose of prednisone at RTX initiation, mg/d [IQR 25th–75th]

19 (5, 30)

Need for oxygen theratpy at RTX initiation

12 (43%)

Need for antifibrotic therapy

3 (11%)

%pFVC at first RTX infusion, mean ± SD [IQR 25th–75th]

69.8 ± 19.6 (52.5 – 76.7)

%pDLCO at first RTX at first RTX infusion, mean ± SD [IQR 25th–75th]

43.4 ± 14.6 (32 – 52)